AU2022402512A1 - Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer - Google Patents

Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer Download PDF

Info

Publication number
AU2022402512A1
AU2022402512A1 AU2022402512A AU2022402512A AU2022402512A1 AU 2022402512 A1 AU2022402512 A1 AU 2022402512A1 AU 2022402512 A AU2022402512 A AU 2022402512A AU 2022402512 A AU2022402512 A AU 2022402512A AU 2022402512 A1 AU2022402512 A1 AU 2022402512A1
Authority
AU
Australia
Prior art keywords
cancer
alkyl
bid
combination
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022402512A
Other languages
English (en)
Inventor
Lars ANDERS
Jerry Li
Tun Tun Lin
Todd Lee Vanarsdale
Ping Wei
Jing Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2022402512A1 publication Critical patent/AU2022402512A1/en
Priority to AU2026201311A priority Critical patent/AU2026201311A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022402512A 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer Abandoned AU2022402512A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201311A AU2026201311A1 (en) 2021-12-02 2026-02-20 Methods and dosing regimens comprising a CDK2 inhibitor and a CDK4 inhibitor for treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163285457P 2021-12-02 2021-12-02
US63/285,457 2021-12-02
PCT/IB2022/061652 WO2023100134A1 (en) 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201311A Division AU2026201311A1 (en) 2021-12-02 2026-02-20 Methods and dosing regimens comprising a CDK2 inhibitor and a CDK4 inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
AU2022402512A1 true AU2022402512A1 (en) 2024-06-20

Family

ID=84462534

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022402512A Abandoned AU2022402512A1 (en) 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
AU2026201311A Pending AU2026201311A1 (en) 2021-12-02 2026-02-20 Methods and dosing regimens comprising a CDK2 inhibitor and a CDK4 inhibitor for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201311A Pending AU2026201311A1 (en) 2021-12-02 2026-02-20 Methods and dosing regimens comprising a CDK2 inhibitor and a CDK4 inhibitor for treating cancer

Country Status (12)

Country Link
US (1) US20250041277A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440575A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024544625A (cg-RX-API-DMAC7.html)
KR (1) KR20240112932A (cg-RX-API-DMAC7.html)
CN (1) CN118647379A (cg-RX-API-DMAC7.html)
AU (2) AU2022402512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241001A1 (cg-RX-API-DMAC7.html)
IL (1) IL312980A (cg-RX-API-DMAC7.html)
MX (1) MX2024006747A (cg-RX-API-DMAC7.html)
TW (1) TWI873485B (cg-RX-API-DMAC7.html)
WO (1) WO2023100134A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202404615B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
EP4604961A1 (en) * 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
EP4719405A1 (en) * 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Also Published As

Publication number Publication date
AU2026201311A1 (en) 2026-03-12
IL312980A (en) 2024-07-01
MX2024006747A (es) 2024-06-19
US20250041277A1 (en) 2025-02-06
KR20240112932A (ko) 2024-07-19
TW202332431A (zh) 2023-08-16
ZA202404615B (en) 2025-12-17
TWI873485B (zh) 2025-02-21
WO2023100134A1 (en) 2023-06-08
CA3241001A1 (en) 2023-06-08
CN118647379A (zh) 2024-09-13
EP4440575A1 (en) 2024-10-09
JP2024544625A (ja) 2024-12-03

Similar Documents

Publication Publication Date Title
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
US12263141B2 (en) Methods for treating cancer
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
CN107864625B (zh) 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
CN115297862A (zh) 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合
US20240000783A1 (en) Combination therapy
BR112019021032A2 (pt) terapia combinada anticâncer
US20230321042A1 (en) Combination therapy
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
RU2849370C1 (ru) Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака
WO2023196910A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
US11684672B2 (en) Combinations of copanlisib with anti-PD-1 antibody
HK40116611A (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
US20240382495A1 (en) Combinations of copanlisib with anti-pd-1 antibody
CA2984357C (en) Methods for treating cancer
HK40096012A (en) Combination therapy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted